[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100489478":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":35,"responsibleParty":72,"collaborators":74,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":18,"enrollmentInfo":87,"targetDuration":18,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":57,"whyStopped":18,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Centre Paul Strauss","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Simultaneous-integrated boost with Intensity-modulated radiation therapy (IMRT)","EXPERIMENTAL","* Planning Target Volume (PTV) 37,5 Gray (Gy): 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days\n* Prescription isodose line (PIL) at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction\n* PTV SIB 45 Gy: 45,0 Gy in 6 fractions of 7,50 Gy at the rate of one fraction each 2 days\n* PIL at 80% corresponding to 36 Gy as total dose, or 6 Gy per fraction",[13],"Radiation: Simultaneous-integrated boost with IMRT",{"label":15,"type":16,"description":17,"interventionNames":18},"Standard IMRT","NO_INTERVENTION","* PTV 37,5 Gy: 37,5 Gy in 6 fractions of 6,25 Gy at the rate of one fraction each 2 days\n* PIL at 80%, corresponding to 30 Gy as total dose, or 5 Gy per fraction\n* No SIB",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"RADIATION","Simultaneous-integrated boost with IMRT","Simultaneous-integrated boost guided by FDOPA-PET",[9],[26,32],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Anne ANTHONY","CONTACT","(0)388252413","33","promotion-rc@institut-strauss.fr",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":31},"MANON VOEGELIN","(0)3 68 33 95 23",[36,56],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"CHRU de Nancy","NOT_YET_RECRUITING","Nancy","De","5400","France","FR",{"type":45,"coordinates":46},"Point",[47,48],6.18496,48.68439,{"lat":48,"lon":47},[51,54],{"name":52,"role":28,"phone":18,"phoneExt":18,"email":53},"Luc TAILLANDIER, Pr","l.taillandier@chru-nancy.fr",{"name":52,"role":55,"phone":18,"phoneExt":18,"email":18},"PRINCIPAL_INVESTIGATOR",{"facility":5,"status":57,"city":58,"state":18,"zip":59,"country":42,"countryCode":43,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"RECRUITING","Strasbourg","67033",{"type":45,"coordinates":61},[62,63],7.74553,48.58392,{"lat":63,"lon":62},[66,68,69],{"name":67,"role":28,"phone":18,"phoneExt":18,"email":31},"Clara LE FEVRE, MD",{"name":67,"role":55,"phone":18,"phoneExt":18,"email":18},{"name":70,"role":71,"phone":18,"phoneExt":18,"email":18},"Caroline BUND, MD, PhD","SUB_INVESTIGATOR",{"type":73,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[75],{"name":76,"class":77},"Centre Georges François Leclerc","UNKNOWN","100489478","phase-2-contribution-from-pet-dopa-in-glioblastoma-re-irradiation---a-randomized-phase-ii-study-100489478",false,"NCT05653635","Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study","ReciDOPA","Inclusion Criteria:\n\n* Age \\> 18 years\n* Glioblastoma, World Health Organization (WHO) grade IV, histologically proven\n* Performance status 0, 1 or 2\n* Neurological status ≥ 2\n* Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)\n* Radiological proven recurrence according to 1 and 2 criteria, Wen et al\n* Remaining node after partial surgery post-recurrence\n* 1 to 3 recurrence site(s) \\\u003C 35 mm in wide axis and separated by at least 5 mm\n* Volume of each lesion \\\u003C 35 mL\n* Distance between recurrence node(s) and optic nerves (left and right), chiasma and\u002For cerebral trunk \\> 10 mm\n\nExclusion Criteria:\n\n* Patient with contraindication to MRI or PET\n* Glioblastomatose\n* Pregnancy or breastfeeding\n* Patient that do not understand French\n* Patient without affiliation to the national or local social security\n* Patients not able to comply to the protocol assessments for geographic, social or psychological reasons\n* Minor or patients placed under guardianship or supervision\n* Patients deprived of liberty\n* Patients placed under judicial protection\n* Patients that are not able to express their consent","ALL","18 Years",{"count":88,"type":89},54,"ESTIMATED","INTERVENTIONAL",[92],"PHASE2","ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.",[95],"Glioblastoma",[95,97],"Simultaneous Integrated Boost","2026-02-02",{"date":100,"type":101},"2026-02-04","ACTUAL",{"date":103,"type":89},"2026-03-01",{"date":105,"type":89},"2028-09-01",{"name":5,"class":6},2]